Drug news

Passeo-18 Lux Balloon study success with femoropopliteal lesions

Read time: 1 mins

Last updated:21st May 2012

Published:21st May 2012

Source: Pharmawand

Six-month results from the BIOLUX P-I study, demonstrating excellent safety and efficacy results for the Biotronik Passeo-18 Lux Paclitaxel Releasing Balloon, were presented on Thursday, May 17, 2012, at the EuroPCR 2012 congress by Dr. Andrej Schmidt, Chief Angiologist at Herzzentrum/Park- Krankenhaus, Leipzig, Germany.The Passeo-18 Lux Paclitaxel Releasing Balloon is a novel approach for treating de novo and restenotic femoropopliteal lesions. The device is based on the proven Passeo-18 percutaneous transluminal angioplasty (PTA) catheter, which is then coated with a matrix of proven antiproliferative paclitaxel and the biocompatible butyryl-tri-hexyl citrate (BTHC) excipient�enabling an optimal drug transfer to the target lesion tissue. In addition, Passeo-18 Lux features a unique, protective insertion aid to facilitate easier device introduction and handling.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older.- Vertex.

Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of Kayydeco (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

1 mins

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 min

Drug news

CHMP positive for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.- Idorsia Ltd.

Idorsia Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

1 min

See all news